NASDAQ:ERYP - Erytech Pharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $7.7486 -0.25 (-3.13 %) (As of 01/23/2019 03:12 PM ET)Previous Close$8.00Today's Range$7.54 - $7.748652-Week Range$5.45 - $23.46Volume104 shsAverage Volume3,765 shsMarket Capitalization$138.93 millionP/E Ratio-2.33Dividend YieldN/ABeta0.79 ProfileDiscussionAnalyst RatingsChartEarningsInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ERYTECH Pharma S.A., a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia. It is preparing for the launch of a pivotal Phase III clinical trial of eryaspase in the United States and Europe. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria and with Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is based in Lyon, France. Receive ERYP News and Ratings via Email Sign-up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ERYP Previous Symbol CUSIPN/A Webwww.erytech.com Phone33-4-78-74-44-38Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E Ratio-2.33 Forward P/E Ratio-2.99 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.98 per share Price / Book0.65Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees114 Outstanding Shares17,930,000Market Cap$138.93 million OptionableNot Optionable Erytech Pharma (NASDAQ:ERYP) Frequently Asked Questions What is Erytech Pharma's stock symbol? Erytech Pharma trades on the NASDAQ under the ticker symbol "ERYP." When is Erytech Pharma's next earnings date? Erytech Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, April 23rd 2019. View Earnings Estimates for Erytech Pharma. What is the consensus analysts' recommendation for Erytech Pharma? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erytech Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Erytech Pharma. Has Erytech Pharma been receiving favorable news coverage? News articles about ERYP stock have trended negative on Wednesday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Erytech Pharma earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the next few days. Who are some of Erytech Pharma's key competitors? Some companies that are related to Erytech Pharma include Adaptimmune Therapeutics (ADAP), PDL BioPharma (PDLI), Gritstone Oncology (GRTS), Mesoblast (MESO), Agenus (AGEN), DBV TECHNOLOGIE/S (DBVT), Nightstar Therapeutics (NITE), Scholar Rock (SRRK), Cellular Biomedicine Group (CBMG), CASI Pharmaceuticals (CASI), Krystal Biotech (KRYS), Replimune Group (REPL), Avrobio (AVRO), MeiraGTx (MGTX) and Voyager Therapeutics (VYGR). Who are Erytech Pharma's key executives? Erytech Pharma's management team includes the folowing people: Mr. Gil Beyen, Chairman & CEO (Age 56)Mr. Jérôme Bailly Pharm.D., VP, Director of Pharmaceutical Operations & Deputy GM (Age 39)Mr. Eric Soyer, CFO & COO (Age 52)Dr. Alexander Scheer, Chief Scientific Officer (Age 56)Naomi Eichenbaum, Director Investor Relations When did Erytech Pharma IPO? (ERYP) raised $125 million in an initial public offering on Friday, November 10th 2017. The company issued 5,300,000 shares at a price of $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF acted as the underwriters for the IPO and JMP Securities was co-manager. How do I buy shares of Erytech Pharma? Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Erytech Pharma's stock price today? One share of ERYP stock can currently be purchased for approximately $7.7486. How big of a company is Erytech Pharma? Erytech Pharma has a market capitalization of $138.93 million. The company earns $-37,890,000.00 in net income (profit) each year or ($3.33) on an earnings per share basis. Erytech Pharma employs 114 workers across the globe. What is Erytech Pharma's official website? The official website for Erytech Pharma is http://www.erytech.com. How can I contact Erytech Pharma? Erytech Pharma's mailing address is 60 AVENUE ROCKEFELLER, LYON I0, 69008. The company can be reached via phone at 33-4-78-74-44-38 or via email at [email protected] MarketBeat Community Rating for Erytech Pharma (NASDAQ ERYP)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 89 (Vote Outperform)Underperform Votes: 115 (Vote Underperform)Total Votes: 204MarketBeat's community ratings are surveys of what our community members think about Erytech Pharma and other stocks. Vote "Outperform" if you believe ERYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ERYP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/23/2019 by MarketBeat.com StaffFeatured Article: What is a Derivative?